Delsia, 3 mg+0.03 mg 21 pcs

Contraception.

Active ingredient

How to take, the dosage

Interaction

Contraindications

Side effects

Organ class system

Income rate of adverse reactions

Frequencies

(≥1/100 and < 1/10)

Infrequent

(≥1/1000 and < 1/100)

Rarely(≥1/10000 and < 1/1000)

Immune system disorders

Hypersensitivity reactions, bronchial asthma

Mental disorders

Depressive states

Libido changes

Nervous system disorders

Headache, migraine

/p>

Hearing and labyrinth disorders

Hearing impairment

Vascular disorders

High blood pressure, low blood pressure

Venous or arterial thromboembolism*

Gastrointestinal disorders

Mammary gland enlargement, vaginitis

Mammary gland discharge

General disorders and disorders at the site of administration

Fluid retention, change in body weight

* Venous or arterial thromboembolism includes the following nosological forms: Peripheral deep vein occlusion, thrombosis and thromboembolism/pulmonary occlusion, thrombosis, thromboembolism and myocardial infarction/cerebral infarction and stroke.

The following adverse reactions have been reported in women using OCs, with very rare occurrence or delayed symptoms believed to be related to taking OCs:

Breast cancer (see Special Indications);

– liver tumors (benign and malignant);

– increased blood pressure:

– pancreatitis in women with hypertriglyceridemia;

– the appearance or worsening of conditions whose association with taking OC is not conclusively established: porphyria epilepsy, uterine myoma, systemic lupus erythematosus (SLE), herpes in pregnancy, Sydenham’s chorea, hemolytic-uremic syndrome, cholestatic jaundice and/or pruritus associated with cholestasis: Cholelithiasis; otosclerosis with hearing impairment;

– impaired liver function;

– changes in glucose tolerance and development of insulin resistance:

– chloasma;

– Crohn’s disease, ulcerative colitis.

In women with hereditary angioedema, taking estrogen may cause or exacerbate its symptoms.

Overdose

Similarities